We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) this week highlighted varying sentiments regarding the company's stock prospects and potential takeover interest. A participant expressed skepticism about a £7-9 bid being adequate, while another reported selling shares, suggesting fluctuating trading dynamics. Notably, discussions revealed apprehensions regarding OXB's defenses against opportunistic bids, with sentiments emerging that the company's current share price may suggest vulnerability. This concern was echoed when one investor observed, “I have to say that the impression I took from the AGM was that there was a feeling of potential vulnerability to an opportunistic bid.”
In terms of financial outlook, speculation on OXB’s revenues for the upcoming year indicated a prediction of approximately £180 million, pointing towards a year of record revenue. Quotes such as "the behavior of the company hasn't appeared to be helping their share price" encapsulated the frustration of investors amid perceived underperformance and challenges in the market context. Despite these concerns, discussions about the company's strategic position and future prospects remained active, with hopes for a more stable and significantly valued future. Several participants highlighted the potential impact of OXB's reintegration into indices like the FT250 as a catalyst for renewed investor interest. Overall, while some investors remain hopeful about OXB's future growth, underlying worries continue to cloud investor sentiment regarding its valuation and the competitive pharmaceutical market.
Show more
Oxford Biomedica Plc (LSE: OXB) has reported several key developments in recent weeks, highlighting its ongoing strategic initiatives and governance changes. Notably, as of December 2, 2024, the company's total issued share capital stands at 105,938,933 ordinary shares, which shareholders can use for determining notification obligations under the FCA's Disclosure Guidance. Additionally, new executive compensation arrangements were announced, including the grant of long-term incentive plan (LTIP) awards to key management, scaled back by 20% as part of best practice governance.
The company is also expanding its engagement in the biopharmaceutical community, with a forthcoming free webinar scheduled for December 9, 2024, focused on the use of advanced robotics in accelerating the development of viral vector products. This reflects OXB's commitment to innovation in cell and gene therapy manufacturing. Furthermore, the Board has undergone changes with the appointment of Colin Bond as a new Non-Executive Director, effective January 1, 2025, as part of planned succession efforts. These developments demonstrate OXB's proactive approach to governance and its focus on enhancing operational capabilities within the competitive biopharmaceutical landscape.
Show more
Signal Update - british bulls 18/10 went back long from short, a nasty bear trap for the shorters from 385p proven to have failed :) |
Strong bounce back to end the week. Enjoy the weekend all LTH's, look forward to seeing what happens Monday. |
I find the current valuation quite frustrating. |
Harry, at least stand in the street and do the 5 minute clap for Frank if we close about 4...within nibbling distance...of course we get your wider point...but these 30 pence from 370 to 400 have been like getting blood out of a stone so fierce has been the resistance... |
I realise I'm in stuck record mode here, but I really do think it needs a very significant RNS from Frank sometime in the next 25 working days to get us back into the FT250 this year. |
DC...quoted 3.94 to buy very small amount :) |
Who knows Dom? |
385p seems to be the 'right' price atm, but wait until the close, eh? |
takeiteasy, yes, and you wonder who has the heft to say to the mms "take it down another 20 pence and I'll buy tens of thousands"? I can think of one candidate. |
Interesting Santar, |
I don't subscribe, but one of these is OXB |
We my be luckier (breakout wise) this time as the traders have done the pull down only to be met with net buyers....so they are not sitting on the fence think a quick short might get them pile of cheaper shares...let's see....not often you see a market try this hard to keep a lid on :) |
It's also four fat ladies. I'll ask Mystic meg. |
Harry, that's auspicious. 8 in Thai is baht - which also means money (Thai Baht), so that is a very lucky number - money money money money! |
PB, |
Gareth, |
Tedious isn't it yet another ground hog day |
Maybe 2 plus 2 equals 5 Mr President, Sir but it's possible and if so..... |
I'm going to sit on the fence Dom. |
It should have been 12 months ago Mr President. We know that WHO require manufacturers on each continent to reduce risk. However, could it be that the £50m was a worthwhile 'cover' in case of a lost argument for doing it all in India? |
I used the wrong name Phil, but I meant the closing slide of a presentation always used to be something like "Expected Catalysts" or "Potential Newsflow" (it's had many names) where the presentation ends with a pointer to what might happen over the next period or two. |
There is a Meet Us page Harry, got a full schedule |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions